Equillium, Inc. announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono?s three-month option exercise period to acquire Equillium?s rights to itolizumab.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.761 USD | -4.99% |
|
-48.13% | +5.46% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.46% | 28.24M | |
+47.03% | 765B | |
-6.79% | 354B | |
+19.01% | 331B | |
+8.75% | 299B | |
+18.89% | 248B | |
-2.09% | 219B | |
+10.88% | 216B | |
+4.92% | 164B | |
-2.80% | 162B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease